TW202134273A - 藉由投予ｉｌ－３３拮抗劑治療ｃｏｐｄ的方法 - Google Patents

藉由投予ｉｌ－３３拮抗劑治療ｃｏｐｄ的方法 Download PDF

Info

Publication number
TW202134273A
TW202134273A TW109143074A TW109143074A TW202134273A TW 202134273 A TW202134273 A TW 202134273A TW 109143074 A TW109143074 A TW 109143074A TW 109143074 A TW109143074 A TW 109143074A TW 202134273 A TW202134273 A TW 202134273A
Authority
TW
Taiwan
Prior art keywords
antibody
copd
subject
moderate
administered
Prior art date
Application number
TW109143074A
Other languages
English (en)
Chinese (zh)
Inventor
雷歐萊特 阿布杜萊
亞歷山大 巴迪
黛柏拉 杜柯維克
海蓮恩 古拉歐科
安卓亞斯 杰索
羅曉東
賀里柏特 史托丁格
艾瑞兒 泰普
馬歇拉 魯迪
尼奇爾 厄敏
錫范 哈瑞爾
查德 尼汶斯
Original Assignee
法商賽諾菲生物技術公司
美商再生元醫藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 法商賽諾菲生物技術公司, 美商再生元醫藥公司 filed Critical 法商賽諾菲生物技術公司
Publication of TW202134273A publication Critical patent/TW202134273A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
TW109143074A 2019-12-06 2020-12-07 藉由投予ｉｌ－３３拮抗劑治療ｃｏｐｄ的方法 TW202134273A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962944878P 2019-12-06 2019-12-06
US62/944,878 2019-12-06
US202062964966P 2020-01-23 2020-01-23
US62/964,966 2020-01-23
US202063082502P 2020-09-24 2020-09-24
US63/082,502 2020-09-24

Publications (1)

Publication Number Publication Date
TW202134273A true TW202134273A (zh) 2021-09-16

Family

ID=74104197

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109143074A TW202134273A (zh) 2019-12-06 2020-12-07 藉由投予ｉｌ－３３拮抗劑治療ｃｏｐｄ的方法

Country Status (12)

Country Link
US (1) US20210230265A1 (enExample)
EP (1) EP4069365A1 (enExample)
JP (2) JP7696900B2 (enExample)
KR (1) KR20220110553A (enExample)
CN (1) CN114786775A (enExample)
AU (1) AU2020398168A1 (enExample)
BR (1) BR112022010934A2 (enExample)
CA (1) CA3160521A1 (enExample)
IL (1) IL293544A (enExample)
MX (1) MX2022006812A (enExample)
TW (1) TW202134273A (enExample)
WO (1) WO2021113707A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021258255A1 (en) * 2020-04-22 2022-10-27 The Board Of Regents Of The University Of Texas System Medication return platform for extracting value from unused medications
TW202540173A (zh) * 2024-04-04 2025-10-16 英商梅迪繆思有限公司 治療及選擇對象之方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
WO2015057668A1 (en) * 2013-10-15 2015-04-23 Medimmune, Llc Methods for treating chronic obstructive pulmonary disease using benralizumab
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法

Also Published As

Publication number Publication date
CA3160521A1 (en) 2021-06-10
CN114786775A (zh) 2022-07-22
WO2021113707A1 (en) 2021-06-10
EP4069365A1 (en) 2022-10-12
BR112022010934A2 (pt) 2022-11-29
JP2025164767A (ja) 2025-10-30
MX2022006812A (es) 2022-08-25
IL293544A (en) 2022-08-01
JP2023505215A (ja) 2023-02-08
KR20220110553A (ko) 2022-08-08
AU2020398168A1 (en) 2022-07-28
US20210230265A1 (en) 2021-07-29
JP7696900B2 (ja) 2025-06-23

Similar Documents

Publication Publication Date Title
JP7315545B2 (ja) Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法
AU2025205430A1 (en) Methods for treating nasal polyposis by administering an IL-4R antagonist
JP6861630B2 (ja) Ｉｌ−４ｒアンタゴニストの投与により鼻ポリープを伴う慢性副鼻腔炎を処置する方法
EP3973987B1 (en) Combination comprising an il-4r antagonist, a corticosteroid and a long-acting beta2-adrenergic agonist for treating asthma
AU2020266593B2 (en) Methods for treating or preventing asthma by administering an IL-33 antagonist
JP2026068738A (ja) Ｉｌ－３３アンタゴニストおよび／またはｉｌ－４ｒアンタゴニストを投与することによりアレルギー性喘息を治療するまたは予防するための方法
JP2025164767A (ja) Ｉｌ－３３アンタゴニストを投与することによりｃｏｐｄを治療するための方法
AU2024241290A1 (en) Methods for treating chronic obstructive pulmonary disease (copd) by administering an il-4r antagonist
JP6898421B2 (ja) Ｉｌ−４ｒアンタゴニストの投与により鼻茸を処置する方法
JP2021063122A (ja) Ｉｌ−４ｒアンタゴニストの投与により鼻ポリープを伴う慢性副鼻腔炎を処置する方法
RU2838119C2 (ru) Способы лечения или предупреждения астмы посредством введения антагониста il-33
EA052377B1 (ru) Применение антитела, которое специфически связывает il-33, для лечения copd
EA050548B1 (ru) Способы лечения или предупреждения аллергической астмы посредством введения антагониста il-33 и/или антагониста il-4r
TW202544036A (zh) 用抗ｔｓｌｐ抗體治療慢性阻塞性肺病
WO2025221640A1 (en) Methods for treating chronic rhinosinusitis without nasal polyps by administering an il-4r antagonist
HK40070002B (en) Combination comprising an il-4r antagonist, a corticosteroid and a long-acting beta2-adrenergic agonist for treating asthma
JP2020105193A (ja) Ｉｌ−４ｒ拮抗薬の投与により喘息を処置または予防するための方法